At-Home Smell Test Can Help ID Risk for Cognitive Impairment
By Elana Gotkine HealthDay Reporter
WEDNESDAY, April 2, 2025 -- The digital remote AROMHA Brain Health Test (ABHT) can discriminate cognitively normal (CN) older adults from those with cognitive impairment, according to a study published online March 24 in Scientific Reports.
Benoît Jobin, Ph.D., from Massachusetts General Hospital in Boston, and colleagues developed the ABHT, an at-home odor identification, discrimination, memory, and intensity assessment, which was self-administered among 127 CN individuals (English and Spanish speaking), 34 participants with subjective cognitive complaints (SCC), and 19 participants with mild cognitive impairment (MCI). The test was self-administered remotely at home under unobserved (CN participants) and observed (CN, SCC, and MCI) modalities and in-person with a research assistant present (CN, SCC, and MCI).
The researchers found that with age, there was a decrease in odor memory, identification, and discrimination scores. In addition, compared with the CN and SCC groups, the MCI group had lower olfactory identification and discrimination, independent of age, sex, and education.
"These results suggest that the ABHT could be used in clinical research settings in different languages to explore the utility of olfactory biomarkers to predict the presence of blood-based, image-based, or cerebrospinal fluid-based biomarkers of neurodegenerative disease and longitudinal development of clinical symptoms," the authors write.
Several authors disclosed financial ties to Aromha.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted April 2025
Read this next
BRCA Mutations Linked to Breast Implant Anaplastic Large Cell Lymphoma
WEDNESDAY, June 25, 2025 -- For women with breast cancer (BC), BRCA mutations are associated with increased risk of developing breast implant–associated anaplastic large...
ADA: Orforglipron Reduces Glycated Hemoglobin in Early Type 2 Diabetes
WEDNESDAY, June 25, 2025 -- The oral small-molecule glucagon-like peptide-1 receptor agonist, orforglipron, reduced glycated hemoglobin (HbA1c) over 40 weeks in adults with early...
Paternal Mental Distress Linked to Poorer Offspring Development
WEDNESDAY, June 25, 2025 -- Paternal mental distress is associated with poorer child development, according to a study published online June 16 in JAMA Pediatrics. Genevieve Le...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.